Temporary treatment during primary HIV infection does not affect virologic response to subsequent long-term treatment.
Temporary cART during primary HIV-infection (PHI) did not select for drug resistance mutations after treatment interruption and did not affect the subsequent virological response to long-term cART. Our data demonstrate that fear of drug resistance development is not a valid argument to refrain from temporary early treatment during PHI.
Academic Medical Center, University of Amsterdam, Department of Internal Medicine, Division of Infectious Diseases, Center for Infection and Immunity Amsterdam, Amsterdam, the Netherlands.
Marlous L
ML
Grijsen
Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam, the Netherlands.
Ferdinand W N M
FW
Wit
Academic Medical Center, University of Amsterdam, Department of Medical Microbiology, Amsterdam, the Netherlands.
Suzanne
S
Jurriaans
Leiden University Medical Center, Department of Infectious Diseases, Leiden, the Netherlands.
Frank P
FP
Kroon
Haga Hospital, location Leyenburg, Department of Internal Medicine, The Hague, the Netherlands.
Emile F
EF
Schippers
Radboud University Medical Center, Department of Internal Medicine, Nijmegen, the Netherlands.
Peter
P
Koopmans
HIV Monitoring Foundation, Amsterdam, the Netherlands.
Luuk
L
Gras
Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam, the Netherlands.
Joep M A
JM
Lange
Academic Medical Center, University of Amsterdam, Department of Internal Medicine, Division of Infectious Diseases, Center for Infection and Immunity Amsterdam, Amsterdam, the Netherlands.
Jan M
JM
Prins
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D024882:Drug Resistance, Viral; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D008134:Long-Term Care; D008297:Male; D012367:RNA, Viral / Q000032:analysis; D019562:Viral Load / Q000187:drug effects*
D019380:Anti-HIV Agents; D012367:RNA, Viral